Business Description
C4 Therapeutics Inc
NAICS : 541714
SIC : 2834
ISIN : US12529R1077
Share Class Description:
CCCC: Ordinary SharesDescription
C4 Therapeutics Inc is a biopharmaceutical company advancing targeted protein degradation science to develop a new generation of small-molecular medicines to transform how the disease is treated. Its TORPEDO platform enables the discovery of a new class of targeted investigational small-molecule medicines called protein degraders.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 3.81 | |||||
| Equity-to-Asset | 0.65 | |||||
| Debt-to-Equity | 0.28 | |||||
| Debt-to-EBITDA | -0.65 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -0.96 | |||||
| Beneish M-Score | 8.34 | |||||
| WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -47.7 | |||||
| 3-Year EBITDA Growth Rate | 23 | |||||
| 3-Year EPS without NRI Growth Rate | 20.7 | |||||
| 3-Year FCF Growth Rate | 28.5 | |||||
| 3-Year Book Growth Rate | -14.5 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 11.56 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 51.93 | |||||
| 9-Day RSI | 48.64 | |||||
| 14-Day RSI | 45.83 | |||||
| 3-1 Month Momentum % | -20.34 | |||||
| 6-1 Month Momentum % | 6.65 | |||||
| 12-1 Month Momentum % | -6.9 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 6.31 | |||||
| Quick Ratio | 6.31 | |||||
| Cash Ratio | 5.9 | |||||
| Days Sales Outstanding | 81.1 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -12 | |||||
| Shareholder Yield % | -10.2 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -347.2 | |||||
| Net Margin % | -313.35 | |||||
| FCF Margin % | -212.04 | |||||
| ROE % | -43.59 | |||||
| ROA % | -28.28 | |||||
| ROIC % | -81.43 | |||||
| 3-Year ROIIC % | -96.56 | |||||
| ROC (Joel Greenblatt) % | -152.16 | |||||
| ROCE % | -32.09 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 8.59 | |||||
| PB Ratio | 1.27 | |||||
| Price-to-Tangible-Book | 1.27 | |||||
| EV-to-EBIT | -1.11 | |||||
| EV-to-Forward-EBIT | -3.4 | |||||
| EV-to-EBITDA | -1.13 | |||||
| EV-to-Forward-EBITDA | -3.49 | |||||
| EV-to-Revenue | 3.46 | |||||
| EV-to-Forward-Revenue | 4.06 | |||||
| EV-to-FCF | -1.63 | |||||
| Price-to-GF-Value | 0.86 | |||||
| Price-to-Net-Current-Asset-Value | 2.21 | |||||
| Price-to-Net-Cash | 2.53 | |||||
| Earnings Yield (Greenblatt) % | -90.09 | |||||
| FCF Yield % | -23.09 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:CCCC
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
C4 Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 33.668 | ||
| EPS (TTM) ($) | -1.7 | ||
| Beta | 3.4 | ||
| 3-Year Sharpe Ratio | 0.09 | ||
| 3-Year Sortino Ratio | 0.22 | ||
| Volatility % | 266.6 | ||
| 14-Day RSI | 45.83 | ||
| 14-Day ATR ($) | 0.453005 | ||
| 20-Day SMA ($) | 4.257 | ||
| 12-1 Month Momentum % | -6.9 | ||
| 52-Week Range ($) | 3.77 - 11.88 | ||
| Shares Outstanding (Mil) | 70.59 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
C4 Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
C4 Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
C4 Therapeutics Inc Frequently Asked Questions
What is C4 Therapeutics Inc(CCCC)'s stock price today?
The current price of CCCC is $4.38. The 52 week high of CCCC is $11.88 and 52 week low is $3.77.
When is next earnings date of C4 Therapeutics Inc(CCCC)?
The next earnings date of C4 Therapeutics Inc(CCCC) is 2025-02-21 Est..
Does C4 Therapeutics Inc(CCCC) pay dividends? If so, how much?
C4 Therapeutics Inc(CCCC) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers